The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Chakma Justin since 2024.
This trader's CIK number is 1951238.
At the time of last reporting, Chakma Justin was the Chief Business Officer of Ars Pharmaceuticals, Inc.. (stock ticker symbol SPRY).
Also see all insider trading activities at Ars Pharmaceuticals, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2024 | SPRY | 0 | $0 | 529,245 | $7,087,331 | 429,245 | $376,927 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-12-12 | SPRY | Option Ex | 117,333 | .84 | 98,559 |
| 2024-12-13 | SPRY | Option Ex | 27,272 | 1.44 | 39,271 |
| 2024-12-12 | SPRY | Sale | 117,333 | 12.27 | 1,439,089 |
| 2024-12-13 | SPRY | Sale | 27,272 | 12.06 | 328,982 |
| 2024-12-10 | SPRY | Option Ex | 50,000 | .84 | 42,000 |
| 2024-12-10 | SPRY | Sale | 50,000 | 13.15 | 657,650 |
| 2024-12-06 | SPRY | Sale | 50,000 | 14.23 | 711,600 |
| 2024-12-04 | SPRY | Option Ex | 45,000 | .84 | 37,800 |
| 2024-12-05 | SPRY | Option Ex | 49,640 | .84 | 41,697 |
| 2024-12-04 | SPRY | Sale | 45,000 | 13.95 | 627,930 |
| 2024-12-06 | SPRY | Option Ex | 50,000 | .84 | 42,000 |
| 2024-12-05 | SPRY | Sale | 49,640 | 14.13 | 701,661 |
| 2024-12-02 | SPRY | Option Ex | 45,000 | .84 | 37,800 |
| 2024-12-03 | SPRY | Option Ex | 45,000 | .84 | 37,800 |
| 2024-12-02 | SPRY | Sale | 45,000 | 13.67 | 615,240 |
| 2024-12-03 | SPRY | Sale | 45,000 | 13.19 | 593,415 |
| 2024-11-25 | SPRY | Sale | 32,814 | 14.00 | 459,428 |
| 2024-11-26 | SPRY | Sale | 42,186 | 14.05 | 592,586 |
| 2024-11-27 | SPRY | Sale | 25,000 | 14.39 | 359,750 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Chakma Justin (Chief Business Officer of Ars Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.